Provided herein are porphyrinato-lanthanide complexes useful as theranostic agents and methods of preparation and use thereof. The porphyrinato-lanthanide complexes are useful in the treatment and imaging of cancer.

Systems, methods, and computer program products for determining different states of a contrast agent in different types of tissue can involve generating a magnetic resonance waveform for the contrast agent in an examination region that includes multiple tissue types. The contrast agent may have different relaxation-shortening effects in each different tissue type. The generated waveform may be compared to database waveforms to determine the concentration of the contrast agent in each tissue type in the examination region.

Automated processing and radiomic analysis of magnetic resonance imaging (“MRI”), such as multi-contrast MR images, and magnetic resonance fingerprinting (“MRF”) data, such as quantitative parameter maps, are integrated into a single workflow.

Radiomic analysis of multiparametric magnetic resonance imaging (“MRI”) and magnetic resonance fingerprinting (“MRF”) data enhances delineation and mapping of tumor regions. Radiomic features are extracted from MRI and MRF tumor images. Distinct tumor regions, including but not limited to necrotic core, enhancing tumor, and peritumoral white matter, are segmented and mapped. Whole tumor as well as tumor region characteristics are evaluated. Tumors can also be differentiated and classified by pathology, grading, staging, and so on. Tumor infiltration into peritumoral white matter regions can also be mapped for recurrence prediction

Systems and methods are provided for susceptibility contrast imaging of nanoparticles at low magnetic fields. A susceptibility-based MRI technique, such as imaging with a balanced steady-state free precession (bSSFP) pulse sequence, may be used for imaging a contrast agent such as biocompatible superparamagnetic nanoparticles at ultra-low fields. The contrast agent and imaging technique may be used to improving the visibility of anatomical structures and detecting diseases, such as cancer, with low-field MRI.

The present disclosure deals with the quickening of MRI examinations. Subjects of the present disclosure are a method, a system, a computer program product, a use, a contrast agent for use and a kit.

Described herein are positron emission tomography (PET)-electron paramagnetic resonance imaging (EPRI) systems and methods of use. In one example, a PET-EPRI system includes a PET-EPR insert, a PET scanner including one or more solid-state photodetectors, and a subject module that can house a subject for scanning. The PET-EPR insert includes an EPR resonator that can nest inside the PET scanner. The EPR resonator includes a resonator that can receive the subject module, a shield encircling the resonator and one or more rapid scan coils (RS-coils) positioned around the shield. The shield can prevent electrical coupling between the RS-coils and the resonator while being transparent to annihilation photons and magnetic field scans.

A computer-implemented method and system includes accessing neurophysiological and neurovascular data recorded during sleep. A function mapping is executed from said neurophysiological and neurovascular data to a target that is one of a glymphatic flow marker, a molecular analysis marker of neurodegeneration, or a neuroimaging marker of neurodegeneration. A target prediction model is output based on the function mapping. The target prediction model can receive new neurophysiological and neurovascular data and output a predicted marker of neurodegeneration.

Systems, methods, and computer program products are provided for segmenting a brain tumor from various MRI sequencing techniques. A plurality of MRI sequences of a head of a patient are received. Each MRI sequence includes a T1-weighted with contrast image, a Fluid Attenuated Inversion Recovery (FLAIR) image, a T1-weighted image, and a T2-weighted image. Each image of the plurality of MRI sequences is registered to an anatomical atlas. A plurality of modified MRI sequences are generated by removing a skull from each image in the plurality of MRI sequences. A tumor segmentation map is determined by segmenting a tumor within a brain in each image in the plurality of modified MRI sequences. The tumor segmentation map is applied to each of the plurality of MRI sequences to thereby generate a plurality of labelled MRI sequences

A computer-implemented method and system includes accessing neurophysiological and neurovascular data recorded during sleep. A function mapping is executed from said neurophysiological and neurovascular data to a target that is one of a glymphatic flow marker, a molecular analysis marker of neurodegeneration, or a neuroimaging marker of neurodegeneration. A target prediction model is output based on the function mapping. The target prediction model can receive new neurophysiological and neurovascular data and output a predicted marker of neurodegeneration.